StreetInsider.com News Articles

aTyr Pharma expects FDA response on Phase 3 sarcoidosis trial by mid-Sept

Tue, 01 Sep 2026 16:39:05 -0400

aTyr Pharma, Inc. (Nasdaq: ATYR) said it expects to receive a response from the U.S. Food and Drug Administration by mid-September 2026 regarding a protocol the company submitted in June 2026 for a planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.

The planned Phase 3 trial is designed as a global, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of efzofitimod in patients with moderate to severe pulmonary sarcoidosis. The 54-week study would enroll up to approximately 372 patients across two parallel cohorts, randomized equally to receive either 5.0 mg/kg efzofitimod

aTyr Pharma expects FDA response on Phase 3 sarcoidosis trial by mid-Sept

Tue, 01 Sep 2026 16:39:05 -0400

aTyr Pharma, Inc. (ATYR) Tops Q2 EPS by 1c

Mon, 10 Aug 2026 06:00:22 -0400

aTyr Pharma, Inc. (NASDAQ: ATYR) reported Q2 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12).

For earnings history and earnings-related data on aTyr Pharma, Inc. (ATYR) click here.

Form S-8 aTYR PHARMA INC

Fri, 07 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260807/26891104.html

Form S-8 aTYR PHARMA INC

Fri, 07 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260807/26891104.html

Form 10-Q aTYR PHARMA INC For: Jun 30

Fri, 07 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260807/26891054.html

Form 10-Q aTYR PHARMA INC For: Jun 30

Fri, 07 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260807/26891054.html

Form 8-K aTYR PHARMA INC For: Aug 07

Fri, 07 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260807/26890932.html

Form 8-K aTYR PHARMA INC For: Aug 07

Fri, 07 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260807/26890932.html

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Fri, 07 Aug 2026 16:01:00 -0400

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.

Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash

Form SCHEDULE 13G/A aTYR PHARMA INC Filed by: FMR LLC

Thu, 06 Aug 2026 10:15:00 -0400
si-local-file:///var/storage/secattach/20260806/26881016.html

Form SCHEDULE 13G/A aTYR PHARMA INC Filed by: FMR LLC

Thu, 06 Aug 2026 10:15:00 -0400
si-local-file:///var/storage/secattach/20260806/26881016.html

Form 8-K aTYR PHARMA INC For: Jul 30

Fri, 31 Jul 2026 16:45:00 -0400
si-local-file:///var/storage/secattach/20260731/26851392.html

Form 8-K aTYR PHARMA INC For: Jul 30

Fri, 31 Jul 2026 16:45:00 -0400
si-local-file:///var/storage/secattach/20260731/26851392.html